Drug Trial Radar · NCT06751524
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2024
Design
- Study type
- Expanded access
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
- Colorectal Cancer (CRC)
- Pancreatic Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Hepatocellular Carcinoma (HCC)
- Melanoma
- Sarcoma
- Ovarian Cancer
- Prostate Cancer
Interventions
BotensilimabDrug
Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).
BalstililmabDrug
Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.